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Abstract
Overexpression of Hedgehog family proteins contributes to the aetiology of many cancers. To be highly active, Hedgehog
proteins must be palmitoylated at their N-terminus by the MBOAT family multispanning membrane enzyme Hedgehog
acyltransferase (Hhat). In a pancreatic ductal adenocarcinoma (PDAC) cell line PANC-1 and transfected HEK293a cells Hhat
localized to the endoplasmic reticulum. siRNA knockdown showed that Hhat is required for Sonic hedgehog (Shh)
palmitoylation, for its assembly into high molecular weight extracellular complexes and for functional activity. Hhat
knockdown inhibited Hh autocrine and juxtacrine signaling, and inhibited PDAC cell growth and invasiveness in vitro. In
addition, Hhat knockdown in a HEK293a cell line constitutively expressing Shh and A549 human non-small cell lung cancer
cells inhibited their ability to signal in a juxtacrine/paracrine fashion to the reporter cell lines C3H10T1/2 and Shh-Light2. Our
data identify Hhat as a key player in Hh-dependent signaling and tumour cell transformed behaviour.
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Introduction
Hedgehog (Hh) proteins are an important class of secreted
intercellular signaling molecules. In mammals, the three Hh
homologues, Sonic (Shh), Indian (Ihh), and Desert (Dhh)
Hedgehog, play crucial roles in regulation of embryonic develop-
ment of several organs, including pancreas, digestive system, heart,
vascular system and lung. During development, differentiation and
tumourigenesis, targets of Hh signaling are involved in cell
adhesion, signal transduction, cell cycle, apoptosis and angiogen-
esis [1]. In adults, Hh signaling is minimal in many differentiated
tissues, with the exception of stem cells and thymocytes [2].
However, Hh signaling is aberrantly reactivated in ,70% of
pancreatic ductal adenocarcinomas (PDAC; [7]) as well as many
other tumours. Abnormal Hh signaling plays important roles in
the growth of many cancer cell types including pancreatic,
digestive tract, prostate, breast and lung cancers (small cell lung
cancer, SCLC, and non-small cell lung cancer, NSCLC),
squamous cell and basal cell carcinomas, gliomas, medulloblasto-
mas and myeloid leukaemias [3–6]. Some of these are amongst the
most intractable tumors for which no effective therapies exist.
Importantly, overexpression of Hh ligands, rather than mutations
in Hh pathway components, contributes through autocrine,
paracrine or juxtacrine signaling to pathway hyperactivation in
PDAC [7,8], breast [4,5] and lung [9,10] cancers. Thus, blocking
production of active Shh should downregulate its function and
mitigate stimulatory effects on cell growth. Supporting this,
treatment with cyclopamine, a specific inhibitor of the positive
transducer of Hh signaling, Smoothened (Smo), reduces the
viability or proliferation of several cancer cell types (see refs above).
Smo antagonists are under development as cancer therapeutics
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and are in clinical trials for multiple cancers (Hedgehog pathway
inhibitors, ClinicalTrials.gov., National Institutes of Health, June
2012).
Hh proteins are secreted through the secretory pathway via the
endoplasmic reticulum (ER) and Golgi complex, but an unusual
feature is their post-translational modification by addition of a
fatty acid (palmitate, Pal) and cholesterol to the protein [11].
These modifications are essential for the controlled extracellular
spread of Hhs to target cells and their biological activity. During
intracellular transport, the ,45 kDa Shh precursor is palmitoy-
lated on its conserved N-terminal cysteine residue. Concomitantly,
a ,18 kDa N-terminal fragment (Shh-N) and a ,25 kDa C-
terminal fragment (Shh-C) are generated by intein-like autocata-
lytic cleavage catalyzed by Shh-C and, concurrently, cholesterol is
covalently attached to the C-terminus of Shh-N to form the
mature active Shh-Np [12]. In mammals, Shh palmitoylation is
crucial for its biological activity; e.g. removal of the palmitoylation
site abrogates the ability to induce differentiation of E11
telencephalic neurons during rodent ventral forebrain formation
[13]. Palmitoylation also plays a major role in guiding modified
Hh proteins to specific membrane domains [14]. The cholesterol
attached to Shh-Np, on the other hand, enhances its affinity for
cell membranes and regulates its cell surface distribution (e.g. to
membrane microdomains), and also affects its extracellular range
and concentration gradient from the producing cell. Dual
lipidation of Shh improves membrane affinity, and is necessary
for formation of high molecular weight complexes with heparan
sulphate proteoglycans (HSPGs; [12]) which enhances signaling
and in vivo activity [14,15]. These complexes assemble during
transport to the cell surface and are of ill-defined composition, but
have been reported to contain Hh, HSPGs and lipoproteins [16].
However, whether the released multimeric form of Shh still
contains its lipid modifications and is a hetero or homomultimer is
a matter of controversy [17]. Indeed, lipidation of Shh has been
reported to be necessary for the cleavage and release of active Shh
multimers during which the lipidated termini are removed [18].
Hh signaling in receiving cells is regulated by Patched (Ptch) and
Smo [5]. In the absence of Hhs, the heptahelical protein Smo is
inhibited by the Ptch Hh receptors. Hhs bind to Ptch and relieve
inhibition of Smo, allowing activation of downstream signaling,
ultimately via Gli transcription factors in vertebrates. The exact
mechanisms of these inhibitory interactions are unclear; current
models suggest Smo is retained intracellularly in the absence of Hh
and translocates to the plasma membrane when Ptch binds Hh,
localizing in the primary cilium where activation of Gli proteins
occurs [19]. Targets of Hh signaling include several pathway
components, e.g. Ptch, Gli, and upregulation of their expression
can be used to assay Hh pathway activity.
Hedgehog acyltransferase (Hhat) is responsible for palmitoyla-
tion of Hhs [20–22] (note Hhat was previously designated skn, ski,
sit and rasp). It is a member of the MBOAT family of membrane-
bound acyltransferases, predicted to contain between 8–12
transmembrane domains (Figure S1) [23]. These multispanning
transmembrane enzymes usually catalyze the addition of a fatty
acid to membrane-embedded substrates such as lipids [24]. Three
MBOAT family members acylate protein substrates: Hhat,
Porcupine (Porc; substrates Wg/Wnt proteins) and ghrelin O-
acyltransferase (GOAT; octanoylates the substrate ghrelin, an
appetite-controlling peptide) [25,26]. MBOAT proteins contain a
characteristic histidine in one transmembrane domain, being
conserved in most family members and thought to be involved in
their acyltransferase activity based on mutational studies.
We show here, using fluorescent protein fusions and epitope-
tagged Hhat proteins, that Hhat predominantly localizes in the
ER. Hhat knockdown (KD) in the PANC1 PDAC cell line reduces
palmitoylation of Shh, prevents its assembly into multimeric
complexes, causes suppression of signaling through the Hh
pathway, and reduces growth and invasiveness. Growth inhibition
by Hhat KD was also shown for A818 PDAC cells. In addition,
Hhat KD in HEK293a cells constitutively expressing Shh and
A549 human NSCLC cells inhibited their juxtacrine/paracrine
signaling. We demonstrate an important role for Hhat in PDAC
and other tumour cells and provide evidence that Hhat inhibition
is a target for tumour growth suppression.
Materials and Methods
Cell culture and siRNA transfection
Human pancreatic ductal adenocarcinoma PANC1 cells
(ATCC, CRL-1469) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 8% fetal bovine
serum (FBS). A818-1 cells [50] were a gift of Mr. Hemant Kocher
(Barts Cancer Institute, London) cells were grown in DMEM plus
10% FBS, plus 100 u/ml penicillin and 100 mg/ml streptomycin.
The human embryonic kidney 293a (HEK293a) line was
generously provided by Dr. Birgit Leitinger (Imperial College
London). HEK293a cells were maintained in DMEM supple-
mented with 8% FBS. Human A549 non-small cell lung cancer
cells were a kind gift of Prof. Simak Ali (Department of Surgery
and Cancer, Imperial College London) and were maintained in
DMEM supplemented with 10% FBS. Shh-Light2 cells [38] were
a kind gift from Drs. Marta Swierczinska and Suzanne Eaton
(Max Planck Institute for Cell Biology and Genetics, Dresden) and
were grown in DMEM supplemented with 10% FBS, 400 mg/ml
G418 (geneticin, Sigma) and 150 mg/ml Zeocin (Invitrogen).
Mouse C3H10T1/2 osteoblast precursor cells (ATCC CCL-226;
[31]) were a kind gift of Dr. Kay Grobe, University of Muenster,
Germany. Cells were validated by microsatellite genotyping (STR-
PCR based method in May 2013; Public Health England,
Salisbury, UK).
Human Hhat siRNA duplex oligomers Hhat-#1 (sense strand
59-UUAAUCAGGUAUGUGUACAUUCCAGUG-39) were de-
signed and ordered from MWG Biotech. Mutated Hhat siRNA
duplex oligomers (59-UUAAUCAGGCAUAUGUACGUUCCA-
GUG-39) were from Invitrogen. ON-TARGET plus siRNA
against human Hhat (59-AGGACAGUCUGGCCCGAUA-39;
Hhat-#2) and ON-TARGET plus Non-targeting siRNA pool
were from Dharmacon (Thermo Scientific Dharmacon; Epsom,
UK). Another negative control applied in this study was SilencerR
Negative Control #1 siRNA (Hhat-Scr, Ambion).
siRNA transfections were carried out by plating 0.3 million cells
per well in a 6-well plate and 6 h later treated with 20 nM siRNA
oligomers and 3 ml FuGENE 6 Transfection Reagent (Roche) per
reaction. Alternatively, siRNA transfections were carried out using
the Metafectene SI reagent (Biontex, Martinsried/Planegg,
Germany) according to the manufacturer’s instructions. 30 pmol
RNA and 1 ml Metafectene SI reagent were diluted in 30 ml 16
Metafectene SI buffer and allowed to complex for 20 min at room
temperature (RT) in a well of a 48-well plate. In the meantime,
cells were trypsinized and diluted to 0.86105 cells/ml in complete
medium. Suspended cells (250 ml) were added to each well and
plates were shaken to ensure even distribution of the cells and
reagents. Cells were assayed 72 h post-transfection.
Immunoblotting
Immunoblotting was carried out 24 h after transfection of
HEK293 cells with expression vector for Hhat-EGFP. For SDS-
PAGE, 0.4 million cells were harvested and lysed by the addition
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of loading buffer (45 mM Tris (pH 6.8), 10% glycerol, 1% SDS,
20 mM DTT, 0.01% bromophenol blue) followed by syringing.
After electrophoresis, proteins were transferred to nitrocellulose
membranes (Millipore, Bedford, MA, USA), blocked at room
temperature for 1 h in phosphate-buffered saline (PBS) with 5%
skimmed milk, and then incubated with primary antibody for 16 h
at 4uC. Goat polyclonal anti-Patched (ab51983) and mouse
monoclonal a-Tubulin (DM1A, ab49928) were purchased from
Abcam. Rabbit polyclonal anti-GLI-1 (H-300, sc-20687) and
rabbit polyclonal anti-Shh (H-160, sc-9024) were purchased from
Santa Cruz Biotechnology. Mouse monoclonal anti-GFP was from
Roche. Secondary antibodies were horseradish peroxidase (HRP)-
conjugated goat anti-mouse immunoglobulin IgG1, HRP-conju-
gated goat anti-rabbit IgG, and HRP-conjugated donkey anti-goat
IgG (used at 1:20,000; Southern Biotech). Bound immunocom-
plexes were detected using enhanced chemiluminescence detection
reagents (Pierce) and were visualized by exposing the membrane to
x-ray film (Fuji Super RX), or with ECL Plus reagent and the
Ettan DIGE Imager (GE Healthcare).
Immunostaining and fluorescence microscopy
PANC1 cells were seeded onto 6-well plates at a density of
16105 cells/well and transfected with Hhat-EGFP. 48 h after
transfection, the cells were fixed with 4% paraformaldehyde (PFA).
Alternatively, 66104 HEK293a cells stably expressing Hhat-V5
were seeded onto glass coverslips in 24-well plates. 24 h after
plating out, cells were fixed with 3% PFA in 16PBS. Imaging was
performed using a Zeiss LSM510 laser-scanning confocal micro-
scope in the Imperial College Facility for Imaging by Light
Microscopy (FILM). Hhat was visualized with mouse monoclonal
anti-V5 IgG2A (1:200, Invitrogen) followed by Alexa488-conju-
gated anti-mouse IgG2A secondary antibody. Golgi complex was
visualized after staining with mouse monoclonal anti-GM130
IgG1 (1:600, BD Transduction LaboratoriesTM), and ER with
mouse monoclonal anti-protein disulfide isomerase (PDI) IgG1
(1:100, BD Transduction LaboratoriesTM) or anti-calnexin (AF18,
1:50, Sigma) respectively, followed by Alexa568 or Alexa633-
conjugated anti-mouse IgG1 secondary antibodies.
Semiquantitative Reverse Transcription-PCR (RT-PCR) and
qPCR
Total RNA extraction from cultured cells was done with Trizol
(Invitrogen). cDNA was synthesized by random priming from 1 mg
of total RNA with SuperScript II Reverse Transcriptase kit
(Invitrogen), according to the manufacturer’s instructions. Alter-
natively, the cDNA was synthesized by random priming from 1 mg
of total RNA with the GoScript reverse transcriptase kit
(Promega). The following primers were used for the subsequent
PCR: human GAPDH (sense, 59-TTCATTGACCTCAACTA-
CAT-39; antisense, 59-GTGGCAGTGATGGCATGGAC-39);
human b-actin (sense, 59-ATGGATGAGGATATCGCTGCG-
39; antisense, 59-CTAGAAGCATTTGCGGTGCAC-39); human
Shh (sense, 59-CGCACGGGGACAGCTCGGAAGT-39; anti-
sense, 59-CTGCGCGGCCCTCGTAGTGC-39) [26]; human
Ptch (sense, 59-GGTGGCACAGTCAAGAACA-39; antisense,
59-ACCAAGAGCGAGAAATGG-39) [26t]; human Smo (sense,
59-TTACCTTCAGCTGCCACTTCTACG-39; antisense, 59-
GCCTTGGCAATCATCTTGCTCTTC-39) [27]; human Gli1
(sense, 59-TTCCTACCAGAGTCCCAAGT-39; antisense, 59-
CCCTATGTGAAGCCCTATTT-39) [27].
Polymerase chain reaction (PCR) with Taq DNA Polymerase
(Invitrogen) followed the manufacturer’s instructions. Cycling
conditions were: 30 cycles of 30 seconds at 95uC, 30 seconds at
60uC, and 2 minutes/kb at 72uC. PCR products were resolved by
electrophoresis on 1.7% agarose gels and visualized by ethidium
bromide staining.
Hhat knockdown in the siRNA-treated cells was further
validated by qPCR, for which we used the GoTaq qPCR master
mix (Promega). Specifically, cDNA from 15 ng input RNA was
used in a 20 ml reaction in a 96-well thermal plate, in triplicate.
The plates were sealed and run in an ABI 7500 Fast Real-Time
PCR System cycler (Applied Biosystems, Life Technologies).
Cycling conditions: 40–45 cycles of 95uC for 45 sec, 60uC for
30 sec. Data were analyzed using the DDCt method for
determination of relative gene expression by normalization to an
internal control gene (GAPDH) and fold expression change was
determined compared to a control sample treated with non-
targeting siRNA.
Cloning and Expression of Recombinant Hhat
Human Hhat cDNA (Accession No: BC117130) was cloned into
pEGFP-N3 mammalian expression vector at the XhoI and
BamHI sites. Transfections of mammalian expression vectors
were carried out using Lipofectamine 2000 (Invitrogen) or
FuGENE HD (view section above for details; Promega). HA-
Hhat-V5 and Hhat-V5 were created using GatewayH cloning
(Invitrogen) into mammalian expression vector pcDNA-DEST40.
Entry vectors were made by topoisomerase cloning of PCR inserts
into vector pENTR/D-TOPO using pENTR directional TOPO
cloning kit. PCR inserts were amplified from human Hhat cDNA
(Accession No: BC117130) using forward primer 59-CACCATG-
TACCCCTACGACGTGCCCGACTACGCCCTGCCCCGA-
TGGGAACTG-39 or 59-CACCATGCTGCCCCGATGG-39
and reverse primer 59-GTCCGTGGCGTAGGTCTG-39.
Entry vector pENTR/D-TOPO containing Hhat constructs
and destination vector pcDNA-DEST40 were recombined using
LR Clonase II enzyme mix to produce HA-Hhat-V5 or Hhat-V5
expressing constructs. Resulting clones were confirmed by DNA
sequencing.
Click chemistry/in vitro palmitoylation
Forty eight hours after siRNA transfection, culture medium was
changed to DMEM labeling medium (1 mM sodium pyruvate and
50–100 mM azido-palmitate analogue, 15-hexadecynoic acid
YnC15 [28,29] for 16–36 h. Cells were washed in PBS, and cell
extracts were prepared in lysis buffer (1% Triton X-100 and
protease inhibitors (complete protease inhibitor cocktail EDTA-
free, Roche) in PBS, pH 7.4). Equivalent amounts of cell lysates
and medium were immunoprecipitated for Shh separately using
5E1 anti-Shh MAb (purified in this lab from 5E1 hybridoma cells
obtained from the Developmental Studies Hybridoma Bank, USA;
free of any antimicrobial solution or preservatives that could affect
cell viability).
Copper-catalyzed azide-alkyne cycloaddition (CuAAC; click
chemistry, [28–30]) was carried out directly on protein G-agarose
beads using azido-TAMRA-biotin capture reagent [28,29]. In vitro
palmitoylation was detected by fluorescence imaging with an Ettan
DIGE Imager (GE Healthcare, UK). Protein concentrations were
measured using Bio-Rad Protein Assay Reagent (Bio-Rad,
Richmond, CA, USA) following the manufacturer’s suggested
procedure.
Shh oligomerization assay
Seventy two hours after Hhat siRNA transfection, culture
medium was changed to serum-free medium (SFM) for 24 h. Gel
filtration analysis of clarified conditioned SFM was performed by
fast protein liquid chromatography (A¨KTA Protein Purifier,
Amersham Biosciences) using a Superdex200 10/300 GL column
Carcinoma Dependence on Hhat
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(Amersham Biosciences) equilibrated with PBS at 4uC [31]. Eluted
fractions were trichloroacetic acid-precipitated and probed for Shh
by dot blotting with anti-Shh H-160 (Santa Cruz, sc-9024).
Matrigel invasion assay
Biocoat Matrigel Invasion Chambers with 8 mm pores in 6-well
plates (BD Biosciences) were used for invasion assays [32]. To
determine the effect of Hhat knockdown, PANC1 cells were
pretreated with Hhat siRNA (described above) for 72 h before
they were added to the chamber. PANC1 cells were detached with
5 mM EDTA in PBS, resuspended in serum-free DMEM and
added to the upper compartment of the chamber (16105 cells/
well). Conditioned medium (8% FBS) was placed in the lower
chamber. After 24 h incubation at 37uC, the cells on the upper
surface were completely removed by wiping with a cotton swab,
and then the filter was fixed with 100% methanol and stained with
crystal violet solution. Cells that had migrated from the upper to
the lower side of the filter were photographed and counted with a
light microscope (40 fields/filter).
PANC1 proliferation assay
Proliferation was measured in vitro with the vital dye 5(6)-
Carboxyfluorescein diacetate N-succinimidyl ester (CFSE, Sigma),
which is loaded into cells and becomes diluted during subsequent
cell divisions. Briefly, after 24 h of synchronization in serum-free
medium, cells were transfected with siRNAs (test and controls) or
treated with anti-Shh 5E1 blocking antibody (Day 1, 10 mg/ml)
and then all conditions were labeled with 2.5 mM CFSE at 37uC
for 15 min. For some wells, 5E1 treatment was carried out 72 h
after synchronization (Day 4, 10 mg/ml), to mimic the kinetics of
RNAi knockdown. After 8 days of culture, cell division was
indicated by decreased CFSE fluorescence intensity, as analyzed
by flow cytometry. For flow cytometer assessment, PANC1 cells
were removed from plates and resuspended in ice-cold FACS
buffer (1% FBS and 2 mM EDTA in PBS), then analyzed with a
FACScalibur flow cytometer.
Paracrine Hh signaling assay with C3H10T1/2 cells
A549 or HEK293a-Shh cells were seeded in co-culture with
C3H10T1/2 cells in DMEM + 3% FBS at a ratio of 1:2 of cells of
interest to C3H10T1/2 cells. A total of 14,800 cells were seeded
per well in a 96-well plate. For Shh pathway inhibition, medium
was supplemented with 20 mg/ml Shh blocking monoclonal
antibody 5E1 or 5 mM cyclopamine at seeding. For Hhat siRNA
KD, A549 or HEK293a-Shh cells were treated for 48 h with
20 mM siRNA Hhat-#2 59-AGGACAGUCUGGCCCGAUA-39
(Dharmacon) or a pool of four non-targeting siRNAs (ON-
TARGETplus Non-Targeting pool, D-001810-10-05, Dharma-
con), then trypsinized and seeded in co-culture with C3H10T1/2
cells in DMEM + 3% FBS as described. After two days of culture,
medium was removed, cells were washed in PBS and lysed by
gentle shaking on a horizontal shaker on ice for 10 min in 50 ml of
ice-cold lysis buffer (PBS pH 7.4, 0.1% (v/v) Triton-X100,
Complete Mini EDTA-free protease inhibitor (Roche)). Alkaline
phosphatase (ALP) activity was measured using p-nitrophenyl
phosphate as substrate. 5 mg p-nitrophenyl phosphate (Sigma)
were dissolved in 5 ml ALP reagent buffer (1 M diethanolamine
buffer pH 9.8, 0.5 mM MgCl2). 200 ml of ALP substrate solution
were added per well of lysed cells and the reaction was incubated
at room temperature for 1–2 h. Reaction was stopped by addition
of 50 ml 3 M NaOH and absorbance was measured at 405 nm.
Paracrine Hh signaling assay with Shh-Light2 cells
Shh-Light2 cells are an NIH/3T3 cell line commonly used in
Shh reporter assays. These cells stably express a firefly luciferase
gene under a Gli-inducible promoter, as a reporter of Shh activity,
and constitutively express a Renilla luciferase gene in order to
normalize the data to cell numbers. 2.56103 PANC1, 56103
HEK293a or 56103 HEK293a-Shh cells were seeded in a 96-well
plate in co-culture with 106103 Shh-Light2 cells in DMEM
supplemented with 3% FBS; cells were cultured for 72 h. Firefly
luciferase expression was measured using the Dual-Luciferase
reporter system (Promega) according to the manufacturer’s
instructions. Briefly, cells were lysed in 25 ml of passive lysis
buffer, at RT for 15 min with shaking. 5 ml of lysate were then
added to a single well of a black 96-well assay plate (Corning).
20 ml of luciferase assay reagent II were then added, and firefly
luminescence measured for 10 sec. After the measurement, firefly
luciferase was quenched and Renilla luciferase measured by the
addition of 20 ml Stop&Glo reagent. Luminescence was measured
in a FLUOstar Optima plate reader (BMG Labtech, Aylesbury,
UK) and data were normalized to the Renilla luciferase readout.
For Hhat siRNA KD, 26104 PANC1 cells were transfected with
Hhat-9 siRNA as described above. 48 h post-siRNA transfection
the medium was exchanged for DMEM supplemented with 3%
FBS containing 16105 Shh-Light2 cells. Cells were co-cultured for
72 h, and then lysed in 50 ml of passive lysis buffer and luciferase
measured as described above.
Statistical analysis
All experiments were replicated at least three times, and
statistical significance was measured by using the two-tailed t test.
A p value of less than 0.05 was considered to indicate statistical
significance. All signals from immunoblots and dot blots were
quantified using Scion Image software.
Results
Intracellular localization of Hhat to ER
To determine the intracellular localization of Hhat in PANC1
cells, they were transfected with Hhat-EGFP followed by laser
scanning confocal microscopy; anti-GM130 and anti-PDI or anti-
calnexin were used to localize Golgi complex and ER respectively
by immunofluorescence confocal microscopy. Hhat-EGFP was
primarily in the ER (Figure 1A; Pearson correlation coeffi-
cient = 0.6760.20). Z-sections taken every 0.5 mm through the cell
showed insignificant, if any, Hhat within the Golgi complex
(Figure 1A; Pearson correlation coefficient = 0.1260.11). Similar
results were obtained by staining for Hhat-V5 in stably transfected
HEK293a cells (Figure 1B). In this case, the Pearson correlation
coefficient between Hhat-V5 and the ER was 0.7560.06, and
between Hhat-V5 and Golgi was 0.2860.08. Our data differ
somewhat from those of Resh and colleagues who reported
substantial localization to the Golgi complex as well as ER [33].
ER localization of Hhat was the predominant phenotype we
observed in over 50 cells. We tested several commercially available
antibodies reported to be against Hhat but none of these
recognized overexpressed transfected C-terminally V5-tagged
Hhat (data not shown). Attempts to raise our own antibodies to
Hhat have so far been unsuccessful. We are therefore unable at
present to confirm the intracellular localization of endogenous
Hhat.
Carcinoma Dependence on Hhat
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siRNA Knockdown of Hhat in PANC1 and HEK-Hhat-V5
cells
To determine whether Hhat is essential for Shh palmitoylation,
we established conditions for effective KD of Hhat in PANC1
cells. The siRNA KD of Hhat was examined by qPCR using
GAPDH as a loading control. In addition, to determine the
specificity of Hhat siRNA, three negative controls were used: a
non-targeting siRNA, a scrambled siRNA (Hhat-Scr) and a
specific control mutated Hhat-#1 siRNA which contains muta-
tions from the original Hhat-#1 siRNA in the 10th, 13th and 19th
nucleotide to preclude siRNA activity. Our results show that
optimized Hhat-#1 RNAi KD results in a .70% decrease in
Hhat expression in PANC1 cells (Figure 2A), whereas with the
non-targeting siRNA the Hhat level was unaffected (Figure 2A);
similar results were observed with Hhat-Scr siRNA and Mutated
Hhat-#1 siRNA treatment (data not shown). By qPCR, Hhat KD
was quantified as 77% KD with Hhat-#1 and 68% KD with
Hhat-#2 at 72 h compared to mutated Hhat-#1. Hhat KD
achieved when data were compared to Hhat-Scr was 66% with
Hhat-#1 and 71% KD with Hhat-#2 (data not shown). Similar
KD of Hhat was measured by qPCR with HEK293a-Shh (Figure
S2) and A549 cells (data not shown). Due to the lack of a specific
Hhat antibody we were unable to directly confirm KD of
endogenous Hhat at the protein level. However, to provide
evidence that Hhat siRNA KD did effectively reduce Hhat protein
levels, we stably expressed Hhat-V5 at moderate levels in
HEK293a cells and then transfected the cells with Hhat siRNA-
#1 or#2 for 72 h followed by anti-V5 immunoblotting. Figure 2B
and C show that Hhat-#1 and #2 transfection substantially
reduced Hhat-V5 expression by 58.1% and 67.8% respectively.
Knocking down Hhat in PANC1 cells reduces
endogenous Shh palmitoylation and oligomerization and
decreases Shh cellular retention
We established a cell-based Shh palmitoylation assay using the
bioorthogonal Cu(II)-catalyzed azido-alkyne cycloaddition reac-
tion, also called click chemistry [29,30]. In short, proteins
metabolically incorporate the palmitate analogue YnC15 and
are detected following reaction with an azido-TAMRA-biotin tag.
Palmitoylation can be monitored by fluorescence imaging of the
tag and also by anti-Shh immunoblotting which detects a slightly
larger (,3–5 kDa) Shh polypeptide due to tag addition (see Figure
S3). Figure 3A shows that YnC15-tagged Shh could be immuno-
precipitated by 5E1 MAb from cell lysate and medium of control
Figure 1. Localization of Hhat in PANC1 cells. A. Localization of Hhat in PANC1 cells was assessed using Hhat-EGFP transfection and confocal
microscopy combined with immunofluorescence localization of ER (PDI) and Golgi (GM130). B. HEK293a Hhat-V5 stable cells were co-stained for the
V5 epitope with ER (Calnexin) or Golgi (GM130) and nuclei (DAPI). The data show that both Hhat-EGFP and Hhat-V5 localize primarily in ER with little if
any in Golgi apparatus. Scale bar = 10 mm.
doi:10.1371/journal.pone.0089899.g001
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PANC1 cells treated with Hhat-Mut siRNA. Hhat-#1 siRNA
treatment, however, caused a substantial reduction in YnC15-
labeled Shh in both lysate and medium, directly demonstrating
inhibition of Shh palmitoylation by Hhat KD. Interestingly, in the
medium of Hhat-#1 KD cells YnC15-unlabeled Shh was more
abundant than that of control cells, but was less abundant in cell
lysates, suggesting increased release when Hhat is knocked down.
Similar results were obtained in HEK293a-Shh cells using Hhat-
#1 and Hhat-#2 siRNAs (data not shown).
To evaluate the role of Hhat in formation of Shh multimeric
complexes, gel filtration followed by Shh dot blotting were carried
out on PANC1 conditioned medium. Using H-160 anti-Shh dot
blotting (Figure 3B), we showed that most secreted Shh in control
PANC1 culture medium migrated as large multimeric complexes
and only a small portion of Shh migrated as monomers, similarly
to previous studies [15,31]. We analyzed whether Hhat was
involved in this multimeric complex formation by Hhat siRNA
treatment. In conditioned medium from Hhat-#1 siRNA-treated
cells, a large proportion of Shh monomers was detected
(41.269.6%), nearly 20 times higher than in control medium,
whereas Mutated Hhat-#1 siRNA-treated medium shows a
similar pattern to control medium with only 2.161.5% monomer.
These data suggest that KD of Hhat in PANC1 cells causes
decreased Shh multimer secretion and confirms that palmitoyla-
tion of Shh plays a positive role in Shh multimer formation [12].
Knocking down Hhat causes decreased signaling
through the Shh pathway in PANC1 cells
To determine whether Hhat (and hence palmitoylation of Shh)
is required for Shh signaling activity, as indicated by Hhat
knockout mice studies [12], RT-PCR and immunoblotting were
performed in a Hhat-#1 KD time-course experiment; GAPDH
Figure 2. Hhat RNAi KD in PANC1 and HEK293a-Hhat-V5 cells. A. Quantitative RT-PCR was performed using Hhat-specific primers to confirm
target gene knockdown in PANC1 cells following Hhat-#1 and Hhat-#2 siRNA transfection. Hhat expression is normalized with GAPDH and
compared to Non-targeting siRNA control. Error bar represents the standard error of at least three independent experiments performed in duplicate
(**, P,0.01; ***, P,0.001). B. To confirm Hhat KD at the protein level, HEK293a cells stably expressing a pcDNA-DEST40-Hhat-V5 construct at
moderate levels were transfected with the Hhat-#1, Hhat-#2 and Non-targeting siRNAs. 72 h post transfection cells were lysed and Hhat expression
examined by SDS-PAGE followed by western blotting with an anti-V5 antibody. Blots were probed for tubulin as a loading control. C. Densitometry
was performed on the blots in panel B; values were then normalized to the tubulin loading control and compared to the Non-targeting siRNA control.
doi:10.1371/journal.pone.0089899.g002
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and b-Actin were used as loading controls. After Hhat-#1 siRNA
treatment, Ptch and Gli1 mRNA level were decreased in PANC1
cells by ,70% and ,50% respectively, whereas Shh and Smo
showed no significant difference (Figure 4A, B). In PANC1 cells,
Ptch and Gli1 were also similarly reduced at the protein level
(Figure 4C, D). Interestingly, when we examined Shh by
immunoblotting of cell lysates, cell-associated Shh was reduced
,70% at 72 h after Hhat-#1 siRNA treatment (Figure 4C),
consistent with non-palmitoylated Shh not being retained by cells.
This reduction was not due to alteration in Shh mRNA level
(Figure 4A, B). These data show that Hhat KD causes decreased
signaling through the Hh pathway in PANC1 cells and reduced
Shh association with the cells, suggesting that non-palmitoylated
Shh is poorly retained at the cell surface. To confirm that the
effects of Hhat siRNA knockdown in PANC1 cells are due to
reduced canonical Hedgehog signalling we tested whether
inhibition of Shh or Smo phenocopies the effect of Hhat siRNA
KD. This is critical as PANC1 cells have been reported to be
unresponsive to Smo inhibition, displaying Hh/Smo-independent
Gli activation (e.g. by TGFb, [51]). There are conflicting data in
the literature highlighted by the differences seen in PANC1 cells
responsiveness to the Hh pathway [8,51] (and references in file
S1). We therefore inhibited Smo with GDC0449 and Shh with the
antagonist Robotnikin in PANC1 cells, using qPCR for Gli1 as a
readout of Hh pathway activity. Figure S4 shows significant
inhibition of Gli1 expression by both inhibitors, indicating that
Smo and Shh are contributing to downstream Hh signaling in
these cells. Differences in the literature may reflect the properties
of different strains of PANC1 cells, or different experimental
approaches.
PANC1 proliferation is Shh-dependent and inhibited by
knocking down Hhat
To determine the effects of Hhat on PANC1 proliferation,
Hhat-#1 siRNA knockdown combined with CFSE incorporation
were used, followed by flow cytometry analysis. We investigated
whether PANC1 proliferation is Shh-dependent by treating cells
with 5E1 inhibitory antibody for Shh. CFSE intensity in cells
treated with 5E1 on day 1 (5E1 D1 group) was ,30 times higher
than untreated cells (Figure 5A), suggesting that untreated PANC1
cells divide ,4 times faster than 5E1-treated cells over 8 days.
Moreover, cells treated with 5E1 on day 4 (5E1 D4 group; used to
mimic the kinetics of Hhat-#1 siRNA KD) showed ,8 times
higher CFSE intensity compared to untreated cells (NT). Both
results show that PANC1 proliferation was Shh-dependent.
Seven days after transfection, Hhat-#1 siRNA-treated cells had
a significantly higher (,8 times) CFSE fluorescence (.6000)
compared to control Mutated Hhat-#1 siRNA-transfected cells
(,1000) (Figure 5A). These results indicate that siRNA-mediated
KD of Hhat suppresses PANC1 cell proliferation substantially.
We used a different cell proliferation assay to confirm these data
in the A818-1 cell line, established from ascites of a 75 year old
Figure 3. Hhat KD inhibits Shh palmitoylation and multimeric complex formation. A. 48 h after Hhat-#1 siRNA transfection PANC1 cells
were labeled with YnC15, then medium and cell lysates were collected for 5E1 immunoprecipitation, treated by click chemistry and analyzed by Shh
Western blot with H-160 Ab. In both medium and cell lysates, YnC15-labeled Shh was reduced in Hhat-#1 KD cells compared to Mutated Hhat-#1
and control cells. In contrast, YnC15-unlabeled Shh was more abundant in the medium of Hhat-#1 KD cells, but less abundant in cell lysates,
demonstrating increased release when Hhat is knocked down. B. To examine the role of Hhat in Shh oligomerization, 72 h after siRNA transfection of
PANC1 cells the media were subjected to gel filtration chromatography (Superdex200 10/300 GL column). After TCA precipitation, the fractions were
probed by dot blot with anti-Shh H-160 antibody. Untreated and control Mutated Hhat-#1-treated cells showed an abundance of large complexes
migrating near the void volume (Vo), whereas Hhat-#1 siRNA-treated KD cells had a much higher proportion of monomer (Vt represents the total
volume of the column). Experiments were repeated three times with similar results.
doi:10.1371/journal.pone.0089899.g003
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female with a differentiated PDAC [34]. These cells expressed
significant amounts of Shh, as determined by Western blotting
(data not shown). Hhat siRNA KD was optimized for this cell line
and KD efficiency of 80% was achieved with Hhat siRNA #1 and
90% with Hhat siRNA #2 .as determined by qPCR (data not
shown). 56103 A818-1 cells were transfected with Hhat-#1, Hhat-
#2 or non-targeting siRNA in 96-well plates. Cell proliferation
was monitored by measuring DNA content using the CyQUANT
NF cell proliferation assay. Proliferation was significantly inhibited
in the Hhat-#1 and Hhat-#2 siRNA-transfected cells compared
to non-targeting siRNA control at 48 h post-transfection, and for
Hhat-#1 siRNA at 96 h post-transfection (Figure S5). This result
confirms that Hhat KD in PDAC cell lines significantly inhibits
cell proliferation.
Knocking down Hhat inhibits PANC1 invasion
To investigate the contribution of Hhat to the invasive potential
of PANC1 cells, we carried out invasion assays after Hhat KD. We
have previously reported that PANC1 invasion is dependent on
Shh signaling using the blocking antibody 5E1 [15]. When
PANC1 cells were transfected with Hhat-#1 siRNA 24 h prior to
the invasion assay, we observed a significant decrease in the
number of invasive PANC1 cells (6667 cells/well), a level similar
to that previously observed for 5E1 treatment (Figure 5B, C). In
contrast, Mutated Hhat-#1 siRNA control treatment gave similar
Figure 4. Hhat KD reduces Shh signaling in PANC1 cells. To study the role of Hhat in Shh signaling, expression levels of Shh targets Ptch and
Gli1 were examined by both RT-PCR and Western blot after Hhat-#1 KD (A, C). Quantification of results is provided in B and D. Interestingly, cell-
associated Shh protein is reduced by Hhat-#1 KD (C, bottom panel) but Shh mRNA level is unchanged (A), suggesting that Hhat-#1 KD reduces Shh
retention by cells. In combination, this suggests that un-palmitoylated Shh has less ability to associate to cell membranes, but instead is released to
the medium.
doi:10.1371/journal.pone.0089899.g004
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levels (276640 cells/well) to untreated control cells [15]. These
results indicate that expression of Hhat was required for efficient
PANC1 invasion. Importantly, direct cell growth assays showed
that the doubling time for PANC1 cells is ,51 h (data not shown).
The four-fold reduction in invasion observed in 24 h cannot
therefore be solely accounted for by inhibition of cell growth.
Hhat siRNA KD reduces juxtacrine/paracrine signaling
We established an assay for juxtacrine/paracrine Hh signaling
using the reporter C3H10T1/2 cells, a mouse osteoblast
progenitor line which responds to Shh stimulation by differenti-
ating into osteoblasts [35,36], which is marked by induction of
alkaline phosphatase (ALP) after 2–5 days stimulation with Hh
proteins. We tested A549 human NSCLC cells which reportedly
express Shh [10,37]; to test if Shh produced by A549 cells was able
to induce a Hh response in surrounding cells in a juxtacrine/
paracrine fashion, A549 cells were co-cultured with C3H10T1/2
cells. siRNA treatment of A549 cells resulted in 20–60% KD of
Hhat mRNA when assayed by qRT-PCR normalized to GAPDH
expression (Figure 6A). The induction of ALP in C3H10T1/2 cells
Figure 5. Hhat KD inhibits PANC1 proliferation and matrix invasion. A. PANC1 cells were labeled with CFSE at the start of the experiment
and treated with Shh neutralizing antibody 5E1 on Day 1 (5E1 D1) to test whether PANC1 proliferation is Shh dependent. 5E1 treatment on Day 4 (5E1
D4) was used to mimic the kinetics of siRNA KD. Cells were allowed to grow for 8 days during which CFSE dilution gave a measure of cell division. 8
days after transfection with Hhat-#1 siRNA the cells were analyzed by flow cytometry. The Y-axis shows the CFSE mean fluorescence intensity (MFI)
observed from 30,000 cells in each condition. The experiments were repeated three times in triplicate, and statistical significance was measured by
using the two-tailed t test (***, P,0.001). B, C. 72 h after transfection with Hhat-1 siRNA or control Mutated Hhat siRNA PANC1 cells were plated onto
Matrigel invasion chambers for 24 h. Cells that had migrated from the upper to the lower side of the filter were photographed (B) and counted with a
light microscope (40 fields/filter, C). Non-treated (NT) and 5E1-treated cells are shown for comparison in B. The experiments were repeated four times,
and statistical significance was measured by using the two-tailed t test (***, P,0.001).
doi:10.1371/journal.pone.0089899.g005
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by A549 cells was inhibited by Shh-blocking antibody 5E1 (20 mg/
ml) and cyclopamine (5 mM) confirming that the ALP response in
C3H10T1/2 cells was largely due to Shh produced by A549 cells
(Figure 6B). After two days of Hhat-#2 siRNA treatment, A549
cells were co-cultured with C3H10T1/2 cells (ratio 1:2
A549:C3H10T1/2) for two days. The C3H10T1/2 cell response
by ALP production was reduced by 37610% (p=0.036)
compared to treatment with a non-targeting pool of siRNAs
(Figure 6C), showing that Hhat KD indeed leads to a reduction in
juxtacrine/paracrine Shh signaling by A549 NSCLC cells.
To confirm that the response in C3H10T1/2 cells was due to
Shh produced by co-cultured cells, a stable clone of HEK239a
cells expressing plasmid pcDNA-DEST40-Shh, HEK293a-Shh,
was created and was morphologically indistinguishable from
HEK293a wt. Click chemistry experiments further confirmed
that Shh was efficiently palmitoylated in these cells (Figure S3).
HEK293a-Shh cells induced differentiation of C3H10T1/2 cells
while HEK293a wt cells did not. Although HEK293a cells did not
express enough endogenous Shh to be able to induce C3H10T1/2
differentiation, they expressed Hhat which palmitoylated exoge-
nous Shh and which could be modulated by Hhat siRNA. Hhat
siRNA treatment of HEK293a-Shh cells assayed by qPCR on day
2, 3 and 4 showed a decrease in Hhat mRNA (Figure S2 and data
not shown). The level of intracellular Shh in HEK293a-Shh cells
Figure 6. Hhat KD inhibits Hh-mediated juxtacrine/paracrine signaling. A. Hhat-#2 siRNA KD in A549 cells was assessed by qPCR 24–96 h
after siRNA transfection showing 20–60% decrease in Hhat mRNA expression. B. A549 cells co-cultured with C3H10T1/2 cells (1:2 ratio) were treated
with cyclopamine or 5E1 anti-Shh blocking antibody for 2 days and ALP induction in C3H10T1/2 cells was then determined using p-nitrophenyl
phosphate in an ALP assay and measuring absorbance at 405 nm. C. A549 cells treated with Hhat-#2 siRNA for 2 days were co-cultured with
C3H10T1/2 cells (1:2 ratio) and ALP induction was assessed after additional 2 days as in B. The results show a significant reduction (*, P,0.05) in the
ability of A549 cells treated with Hhat-#2 compared to cells treated with non-targeting (NT) siRNA pool to induce ALP production in C3H10T1/2 cells.
The experiments were repeated four times and statistical significance was measured using the paired t test. D. PANC1 and HEK293a-Shh cells induce
luciferase activity in the Shh-Light2 cells when co-cultured for 72 h, while the HEK29a cell line, which does not express Shh, did not show luciferase
activity higher than background levels (Shh-Light2 cells alone). The data shown are representative of five independent experiments and are the
means6 standard error of triplicates. Data were normalized to the Shh-Light2 cell monoculture response (*, P,0.05; **, P,0.01). E. PANC1 cells were
transfected with Hhat-#1, Hhat-#2 or Non-targeting siRNAs. 48 h post-transfection, Shh-Light2 cells were mixed with the transfected cells (2:1 ratio)
and they were co-cultured for 72 h. The data shown are representative of three independent experiments and are the means 6 standard error of
triplicates. Data were normalized to the Non-targeting siRNA response (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0089899.g006
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analyzed by Western blotting showed that Hhat-#2 KD resulted
in a reduction of intracellular Shh, similar to that seen in PANC1
cells in Figure 3A and 4C, consistent with the role of Shh
palmitoylation in the cell as a membrane anchor for the protein
(data not shown).
HEK293a-Shh cells treated with Hhat-#2 siRNA co-cultured
with C3H10T1/2 cells (ratio 1:2) for 2 days during day 2–4 of KD,
resulted in a C3H10T1/2 response decrease of 32610%
compared to non-targeting siRNA, but this did not quite reach
statistical significance. We therefore used the well characterized
Shh-Light2 cell line [38] as a reporter of juxtacrine/paracrine
signaling from HEK293a-Shh cells. Shh-Light2 cells contain a
luciferase gene under the control of a Gli-responsive promoter and
respond to Shh stimulation by inducing Luciferase activity.
Figure 6D shows that HEK293a-Shh cells but not control
HEK293a cells were able to induce luciferase in co-culture with
Shh-Light2 cells. PANC1 cells also induced luciferase expression
by Shh-Light2 cells (Figure 6D), and Hhat KD by Hhat-#2
siRNA treatment reduced this by 44.1% (p=0.0051) (Figure 6E).
Discussion
The increased Hh signaling detected in many types of cancer
and the identification of the significant role it plays in regulating
the stromal environment to promote cancer growth and metas-
tasis, has identified the Hh signaling pathway as a valid target in
cancer. Smo inhibitors, currently under development by several
companies, have great potential but mutations in Smo that make
tumour cells resistant will make them ineffective in time, as has
been found for many drug targets [39]. In this work, we present
evidence that inhibiting the post-translational palmitoylation of
Shh, by knocking down the enzyme Hhat responsible for
palmitoylating Shh, inhibits PDAC cell growth and invasion and
Shh signaling.
Hhat localization was confirmed to be primarily in the ER with
little if any presence in the Golgi complex. This was done in two
separate cell lines, using transfection with a Hhat-GFP fusion
construct in human PANC1 cells, and a similar result was
obtained for Hhat-V5 in transfected HEK293a cells. These data
confirm the major site of Hhat localization as the ER, but in
contrast to work published by Resh and colleagues in transfected
COS-1 cells [33,40] we found very little if any localization to the
Golgi complex. These differences may be due to the use of
different cell types. Using novel bioorthogonal ligation chemistry
[28,29] we have shown that Hhat KD caused near total ablation of
Shh palmitoylation. Hhat KD also resulted in decreased cell-
associated Shh, as expected if Shh acylation was inhibited.
Inhibition of Shh palmitoylation also caused ablation of multi-
meric complex formation, the molecular species which is believed
to be efficiently transported between Shh producing and receiving
cells and to be biologically most active.
PANC1 cells have been reported to depend for their growth on
Shh [8]. Using semi-quantitative RT-PCR and qPCR we show
here that Hhat mRNA could be effectively knocked down in
PANC1 cells by siRNA treatment for 48–72 h and that this
resulted in reduction of target gene expression (Ptch, Gli). Off-
target effects of siRNAs are of course possible but we have
controlled for these by using control non-targeting, scrambled
siRNA (Hhat-Scr) or a control siRNA mutated at every third base
to abrogate interaction with Hhat mRNA which were ineffective,
confirming the specificity of the effect. In addition, no off-target
effects were observed on several other genes (Figure 4A, B). We
used a proliferation assay based on the cytoplasmic fluorescent
marker CFSE to monitor the effect of Hhat KD on PANC1
proliferation. Hhat-#1 siRNA (but not Mutated Hhat-#1) caused
a strong reduction in cell division over 4 days, comparable to that
seen with the Shh-neutralizing mouse monoclonal antibody 5E1.
A Matrigel invasion assay was employed to show that the invasive
properties of PANC1 cells were also dramatically curtailed by
siRNA KD of Hhat (but not by control Mutated Hhat-#1 siRNA),
similar to the effect of 5E1 antibody. Similar results were obtained
in another PDAC cell line, A818-1. Moreover, the decrease in
invasiveness over 24 h of PANC1 cells depleted of Hhat could not
be accounted for by the reduction in cell proliferation during this
time. This provides convincing evidence that Hhat is required for
Shh signaling, proliferation and invasive behaviour of the PANC1
human PDAC cell line and that Hhat KD reverts the transformed
properties of these cells. These results are supported by a recent
paper [41] which showed that Hhat knockdown in NSCLC
inhibited Shh palmitoylation as well as growth and survival of the
tumor cells.
It could be argued that reduced cell viability of PANC1 cells,
A549 or HEK-Shh may account for the reduction of Hh pathway
activity in the signal receiving C3H10T1/2 or Shh-light2 cells,
although the end effect is the same, i.e. oncogenic signaling is
inhibited. We have not addressed the mechanism of the effect in
this manuscript and that would be the subject of further studies.
Also, it seems unlikely that cell death could be accounting for the
observed effects in all three cell lines, especially in the HEK-Shh
cells which are an artificial line and have no dependence on Hh
signaling for their proliferation or survival.
Hhat is an attractive target for therapeutic intervention in the
Hh signaling pathway because it appears to be solely responsible
for acylation of Hhs, and its only known substrates in man are Hh
proteins. Indeed, a mouse knockout of Hhat (called Skn in [12])
has a phenotype very similar to a Shh knockout resulting in
developmental defects and neonatal lethality, indicating the
essential role of Hhat in production of active Hh proteins.
Blocking Shh palmitoylation via Hhat inhibition should be highly
selective and would provide a complementary strategy that could
be used singly or, more likely, in combination with drugs targeted
at signal transduction in the receiving cell or stroma, such as Smo.
Inhibiting an essential Shh modification at the same time as Smo
may be advantageous since, blocking the pathway at two points
might make resistance mutations much less likely. Attacking the
Hh pathway is an attractive strategy because it can not only
directly inhibit tumor cell growth but also interferes with paracrine
signaling between the tumor cells and surrounding stroma [42]
which contributes synergistically to pancreatic tumor progression
[43]. These tumor-stroma interactions can cause desmoplasia,
reducing blood flow to the tumor, thereby preventing access of
conventional anti-cancer agents in PDAC [44]. Drugs against
Hhat should be efficacious, as blocking Hh pathway signaling in
adult animals, at least for short periods, could effectively cause
regression of pancreatic and other digestive tract tumors but had
no obvious deleterious effects on the recipients [8]. As this
manuscript was about to be submitted, Resh and colleagues
reported the identification of selective small molecule inhibitors of
Hhat from a screen of over 63,000 commercially available
compounds [40]. These compounds affect Shh signaling in model
in vitro assays although effects on the growth of tumour cells were
not reported. In addition, two selective small molecule inhibitors of
the Porc MBOAT member have been described [45,46] which
inhibit Wnt acylation and do not affect Hhat, and inhibitors of
GOAT have also been reported [47,48]. The Porc inhibitor C59
inhibited the growth of a Wnt-driven breast cancer cell line and
Wnt signaling, both in vitro and in a mouse xenograft model, with
no apparent toxicity in the mice [46]. This provides considerable
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promise that selective Hhat inhibitors could be identified and serve
as possible therapeutics.
In order to find highly specific and selective pharmacological
agents targeted at Hhat it is important to thoroughly characterize
the biochemistry and cell biology of this acyltransferase. To date
there is little cell biological or biochemical analysis of Hhat from
any species. Buglino and Resh [33] reported some important
characterization of Hhat enzymatic properties in detergent
solution including mutational studies which confirmed roles for
the conserved histidine 379 and the adjacent tryptophan 378
residues in catalytic function, albeit not an absolute requirement
[49]. Future progress will require a thorough molecular charac-
terization of Hhat in its native membrane environment, including
determining its transmembrane topology and crucial catalytic
residues by mutational analysis.
Supporting Information
Figure S1 Transmembrane topology of Hhat predicted
using the TOPCONS Programme.
(TIF)
Figure S2 Hhat mRNA is effectively knocked down by
siRNA treatment in HEK293a-Shh cells. Quantitative RT-
PCR was performed using Hhat-specific primers to confirm target
gene knockdown in HEK293a-Shh cells following Hhat-#1 and
Hhat-#2 siRNA transfection. Hhat expression is normalized to
GAPDH and compared to Non-targeting siRNA control. Error
bar represents the standard error of three independent experi-
ments performed in triplicate (*, P,0.05).
(TIF)
Figure S3 HEK-Shh stable cell line produces palmitoy-
lated Shh. HEK-Shh cells were grown overnight in media that
contained YnC15 or palmitic acid. Cell lysates were prepared and
then treated by click chemistry. Labeled proteins were pulled
down on Neutravidin-coated beads and pulled down proteins were
analyzed by SDS-PAGE and in gel fluorescence (A) and
subsequently by Western blotting using Shh and tubulin antibodies
(B). A. In-gel fluorescence of YnC15-labelled proteins from the
HEK-Shh cell line (right hand 3 lanes). Control cells fed with
palmitic acid (left hand 3 lanes) do not show any fluorescently-
labeled proteins either in the input or following pull down with
Neutravidin-coated beads, clearly indicating that fluorescence is
due to the clicked proteins. B. Gel in image A was transferred to
PVDF membrane and probed with anti-Shh Ab H-160. In the
palmitic acid-fed cells, a single Shh band is seen at 20 kDa;
however, in the YnC15-fed cells, two Shh bands are present, one
at about 25 kDa, representing the YnC15-labeled tagged Shh, and
another band at 20 kDa, representing the unlabeled Shh
molecules. The increased molecular weight is due to the size of
the azido-TAMRA-biotin capture reagent. This is further shown
following Neutravidin pull down of the clicked proteins, as only the
upper YnC15-labeled Shh is seen in the bound proteins lane, while
in the lane containing the unbound fraction the lower band only is
present.
(TIF)
Figure S4 Smo and Shh inhibition by small molecule
inhibitors in PANC1 cells reduces Shh signaling. PANC1
cells were treated with either the Smo inhibitor GDC0449 (A) or
the Shh-binding antagonist Robotnikinin (B) or DMSO control.
Shh signaling was examined by qPCR using Gli1-specific primers
48 h after treatment. A. GDC0449 treatment significantly reduced
Gli1 expression (p = 0.0279). B. Robotnikinin also reduced Gli
expression but did not reach significance. These data indicate that
autocrine Shh signaling can be inhibited in the PANC1 cells used
in this study. Our data are supported by several published studies
on PANC1 cells [1–3]. Gli1 expression is normalized with
GAPDH and compared to DMSO control. Error bar represents
the standard error of n= 4 (GDC0449 data) and n= 3 (Robot-
nikinin data) independent experiments performed in duplicate;
data were analysed in Graphpad Prism by a two-tailed unpaired
student t-test (**, P,0.05; *, P,0.1).
(TIF)
Figure S5 Hhat KD inhibits A818-1 cell proliferation.
For each condition, 26104 A818-1 cells were transfected with the
indicated siRNA and then 56103 cells were plated out in four 96-
well plates. Proliferation was subsequently monitored at specific
time points by measuring the DNA content using the CyQUANT
NF reagent. The Y-axis shows the fluorescence measurements
reported as arbitrary units (AU) in each well for the indicated
condition. Measurements were made using an Ettan DIGE imager
with excitation at 485 nm and emission detection at 530 nm. The
experiments were repeated four times, and statistical significance
was measured by using the two-tailed t test (*, P,0.05).
(TIF)
File S1.
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